These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 26932224)

  • 1. Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics.
    Goel H; Dunbar RL
    Curr Atheroscler Rep; 2016 Apr; 18(4):17. PubMed ID: 26932224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens.
    Dunbar RL; Goel H
    Curr Atheroscler Rep; 2016 Feb; 18(2):11. PubMed ID: 26876225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future of GPR109A agonists in the treatment of dyslipidaemia.
    Wanders D; Judd RL
    Diabetes Obes Metab; 2011 Aug; 13(8):685-91. PubMed ID: 21418500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in niacin and lipid metabolism.
    Kamanna VS; Ganji SH; Kashyap ML
    Curr Opin Lipidol; 2013 Jun; 24(3):239-45. PubMed ID: 23619367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Niacin: the evidence, clinical use, and future directions.
    Villines TC; Kim AS; Gore RS; Taylor AJ
    Curr Atheroscler Rep; 2012 Feb; 14(1):49-59. PubMed ID: 22037771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Niacin as antidyslipidemic drug.
    Julius U
    Can J Physiol Pharmacol; 2015 Dec; 93(12):1043-54. PubMed ID: 26370906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis.
    D'Andrea E; Hey SP; Ramirez CL; Kesselheim AS
    JAMA Netw Open; 2019 Apr; 2(4):e192224. PubMed ID: 30977858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Niacin: an old drug rejuvenated.
    Kamanna VS; Ganji SH; Kashyap ML
    Curr Atheroscler Rep; 2009 Jan; 11(1):45-51. PubMed ID: 19080727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Niacin-a critical component to the management of atherosclerosis: contemporary management of dyslipidemia to prevent, reduce, or reverse atherosclerotic cardiovascular disease.
    Mason CM; Doneen AL
    J Cardiovasc Nurs; 2012; 27(4):303-16. PubMed ID: 21804401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.
    Lauring B; Taggart AK; Tata JR; Dunbar R; Caro L; Cheng K; Chin J; Colletti SL; Cote J; Khalilieh S; Liu J; Luo WL; Maclean AA; Peterson LB; Polis AB; Sirah W; Wu TJ; Liu X; Jin L; Wu K; Boatman PD; Semple G; Behan DP; Connolly DT; Lai E; Wagner JA; Wright SD; Cuffie C; Mitchel YB; Rader DJ; Paolini JF; Waters MG; Plump A
    Sci Transl Med; 2012 Aug; 4(148):148ra115. PubMed ID: 22914621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.
    Vosper H
    Br J Pharmacol; 2009 Sep; 158(2):429-41. PubMed ID: 19627285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPR109A and vascular inflammation.
    Chai JT; Digby JE; Choudhury RP
    Curr Atheroscler Rep; 2013 May; 15(5):325. PubMed ID: 23526298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Niacin in cardiovascular disease: recent preclinical and clinical developments.
    Digby JE; Ruparelia N; Choudhury RP
    Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):582-8. PubMed ID: 22207729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
    Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
    Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicotinic acid: recent developments.
    Kamanna VS; Vo A; Kashyap ML
    Curr Opin Cardiol; 2008 Jul; 23(4):393-8. PubMed ID: 18520725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring niacin-associated skin toxicity (NASTy) stigmata along with symptoms to aid development of niacin mimetics.
    Dunbar RL; Goel H; Tuteja S; Song WL; Nathanson G; Babar Z; Lalic D; Gelfand JM; Rader DJ; Grove GL
    J Lipid Res; 2017 Apr; 58(4):783-797. PubMed ID: 28119443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential.
    Gaidarov I; Chen X; Anthony T; Maciejewski-Lenoir D; Liaw C; Unett DJ
    Cell Signal; 2013 Oct; 25(10):2003-16. PubMed ID: 23770183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
    J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?
    Kamanna VS; Kashyap ML
    Am J Cardiol; 2007 Dec; 100(11 A):S53-61. PubMed ID: 18047854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.